--- title: 'Manufacturing Daily Summary: What Happened on November 9, 2026' headline: Simtra adds sterile injectable capacity in Indiana description: An industry group also urged U.S. drug-supply planners to focus on key starting materials and consider continuous-flow production. url: https://thebench.bio/news/manufacturing/2026-11-09 topic: manufacturing date: '2026-11-09' covers: - '2026-11-09' date_published: '2026-11-09T12:02:39Z' date_modified: '2026-11-10T00:02:10Z' tags: - Industry - Manufacturing sources: 2 publisher: TheBench.Bio --- # Manufacturing Daily Summary: What Happened on November 9, 2026 **Simtra adds sterile injectable capacity in Indiana** An industry group also urged U.S. drug-supply planners to focus on key starting materials and consider continuous-flow production. ## Today in brief Simtra is expanding its Bloomington, Indiana, campus for syringe, vial, freeze-drying and high-potency filling. [1] Plans for the new building include two high-speed syringe lines, a vial line and three freeze-dryers. [1] Brian Doty of the API Innovation Center urged U.S. drug-supply efforts to prioritize key starting materials, the inputs used to make active pharmaceutical ingredients. [2] He said continuous-flow chemistry could make domestic production more practical and fit into existing facilities. [2] ## Simtra expands Bloomington sterile injectable operations Simtra is adding a building at its Bloomington campus for syringe, vial and lyophilization work. [1] The company also bought an adjacent 300,000-square-foot building for its first high-potency filling line in Bloomington. [1] Simtra plans three freeze-dryers to serve two high-speed syringe lines and a vial line in the new building. [1] Bo Watkins said customer demand and perceived gaps in the U.S. sterile injectable market are driving the additions. [1] Watkins said the high-potency operation will draw on manufacturing experience built up over 65 years at Simtra’s Halle site. [1] ## APIIC urges focus on starting materials in drug-supply plans Brian Doty of the API Innovation Center said U.S. sourcing efforts should focus on key starting materials, which are used to make active pharmaceutical ingredients. [2] A study described in Senate testimony found that China was the sole source for 47% of the key starting materials examined for 40 essential medicines often in shortage, where data were available. [2] Doty said foreign suppliers provide the active ingredients used in 83 of the 100 most-prescribed U.S. generic drugs. [2] He said continuous-flow chemistry runs reaction steps in sequence and can produce materials faster than conventional batch processes while using less space. [2] Doty said the smaller footprint could let manufacturers install the process in existing facilities rather than build new plants. [2] He said generic-drug makers need a financial reason to adopt new processes because their margins are narrow. [2] ## The day in numbers - **2 syringe lines**: High-speed lines planned for Simtra’s new Bloomington building. [1] - **300,000 square feet**: Size of the adjacent Bloomington building Simtra acquired for high-potency filling. [1] - **47%**: Share of examined key starting materials for 40 shortage-prone essential medicines reported to come only from China, where data were available. [2] ## Also published - [Supply continuity in clinical trials: Why certification alone is not enough](), Clinical Trials Arena - [Formulation Development Roundup](), GEN - [How can we build trust in model-driven manufacturing?](), PharmaVoice ## Sources 1. [Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions](), BioPharm International, 2026-11-09 2. [China-Sourced KSMs Leave Vital 40 Exposed, APIIC Warns](), Pharmaceutical Commerce, 2026-11-09 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: